Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This study is a multicenter, randomized study, open-label, phase III study.The efficacy of irinotecan and capecitabine combination will be superior to capecitabine alone in term of progression free survival in metastatic breast cancer patients previously treated with anthracycline and taxane.
Critère d'inclusion
- Metastatic breast cancer